WO1996000503B1 - Novel peptides - Google Patents

Novel peptides

Info

Publication number
WO1996000503B1
WO1996000503B1 PCT/US1995/008156 US9508156W WO9600503B1 WO 1996000503 B1 WO1996000503 B1 WO 1996000503B1 US 9508156 W US9508156 W US 9508156W WO 9600503 B1 WO9600503 B1 WO 9600503B1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
ser
sequence
amino acids
oligopeptides
Prior art date
Application number
PCT/US1995/008156
Other languages
French (fr)
Other versions
WO1996000503A1 (en
Filing date
Publication date
Priority claimed from US08/267,092 external-priority patent/US5599686A/en
Priority to AU30922/95A priority Critical patent/AU689934B2/en
Priority to DK95926602T priority patent/DK0771209T3/en
Priority to BR9508151A priority patent/BR9508151A/en
Priority to JP8503422A priority patent/JPH10502619A/en
Priority to MX9700043A priority patent/MX9700043A/en
Priority to AT95926602T priority patent/ATE223224T1/en
Priority to DE69528064T priority patent/DE69528064T2/en
Priority to HU9603564A priority patent/HU220877B1/en
Priority to PL95317872A priority patent/PL186341B1/en
Application filed filed Critical
Priority to NZ290239A priority patent/NZ290239A/en
Priority to RO96-02483A priority patent/RO116198B1/en
Priority to EP95926602A priority patent/EP0771209B1/en
Priority to SK1640-96A priority patent/SK164096A3/en
Priority to UA97010353A priority patent/UA55371C2/en
Publication of WO1996000503A1 publication Critical patent/WO1996000503A1/en
Publication of WO1996000503B1 publication Critical patent/WO1996000503B1/en
Priority to FI965225A priority patent/FI965225A/en
Priority to BG101077A priority patent/BG63453B1/en
Priority to NO965592A priority patent/NO965592L/en
Priority to HK98109815A priority patent/HK1009038A1/en

Links

Abstract

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

Claims

AMENDED CLAIMS[received by the International Bureau on 1 January 1996 (01.01.96); original claim 1 amended; remaining claims unchanged (1 page)]
1. An oligopeptide, not including Semenogelin I and II, that comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen.
2. The oligopeptide according to Claim 1 wherein the sequence of amino acids is
a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),
b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),
c) GlyGluAsnGlyValGhjiysAspValSej<ϊlnXaaSerIleTyr|SerGlnThrGlu (SEQ.ID.NO.: 15) ,
d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu
(SEQ.ID.NO.: 2),
e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),
f) AsnLysAlaSerTyιGln|Ser (SEQ.ID.NO.: 128),
g) SerTyrGln|SerSer (SEQ.ID.NO.: 129);
h) LysTyrGlnlSerSer (SEQ.ID.NO.: 140); or
i) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);
wherein hArg is homoarginine and Xaa is any natural amino acid.
3. The oligopeptide according to Claim 2 wherein the sequence of amino acids is
PCT/US1995/008156 1994-06-28 1995-06-07 Novel peptides WO1996000503A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SK1640-96A SK164096A3 (en) 1994-06-28 1995-06-07 Oligopeptide and a conjugate containing it
RO96-02483A RO116198B1 (en) 1994-06-28 1995-06-07 Oligopeptide and conjugate thereof selectively cleaved by prostate specific antigen
NZ290239A NZ290239A (en) 1994-06-28 1995-06-07 Peptides, oligopeptides with amino acid sequences that are recognised and proteolytically cleaved by free prostate specific antigen, assays and medicaments comprising such peptides
EP95926602A EP0771209B1 (en) 1994-06-28 1995-06-07 Novel peptides
DK95926602T DK0771209T3 (en) 1994-06-28 1995-06-07 New peptides
AT95926602T ATE223224T1 (en) 1994-06-28 1995-06-07 NOVEL PEPTIDES
DE69528064T DE69528064T2 (en) 1994-06-28 1995-06-07 NEW PEPTIDES
HU9603564A HU220877B1 (en) 1994-06-28 1995-06-07 Novel olygopeptides, diagnostic methods for use thereof and conjugates for treatment of prostata cancer
PL95317872A PL186341B1 (en) 1994-06-28 1995-06-07 Novel peptides
AU30922/95A AU689934B2 (en) 1994-06-28 1995-06-07 Novel peptides
BR9508151A BR9508151A (en) 1994-06-28 1995-06-07 Oligopeptide tests to determine the prostate-specific free antigen proteolytic activity in a sample and to identify compounds that inhibit prostate-specific antigen proteolytic activity and conjugate
MX9700043A MX9700043A (en) 1994-06-28 1995-06-07 Novel peptides.
JP8503422A JPH10502619A (en) 1994-06-28 1995-06-07 New peptide
UA97010353A UA55371C2 (en) 1994-06-28 1995-07-06 Oligopeptides comprising amino acid sequences recognized and proteolytically cleaved by free prostate specific antigen, assay for protease activity of prostate specific antigen, method for identification of compounds inhibiting the proteolitical activity of said antigen, therapeutic agents comprising conjugates of such oligopeptides used for treatment of prostate cancer
FI965225A FI965225A (en) 1994-06-28 1996-12-27 New peptides
BG101077A BG63453B1 (en) 1994-06-28 1996-12-27 Peptides
NO965592A NO965592L (en) 1994-06-28 1996-12-27 New peptides
HK98109815A HK1009038A1 (en) 1994-06-28 1998-08-11 Novel peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US267,092 1994-06-28
US08/267,092 US5599686A (en) 1994-06-28 1994-06-28 Peptides
US40483395A 1995-03-15 1995-03-15
US404,833 1995-03-15

Publications (2)

Publication Number Publication Date
WO1996000503A1 WO1996000503A1 (en) 1996-01-11
WO1996000503B1 true WO1996000503B1 (en) 1996-02-22

Family

ID=26952210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008156 WO1996000503A1 (en) 1994-06-28 1995-06-07 Novel peptides

Country Status (27)

Country Link
US (1) US6143864A (en)
EP (1) EP0771209B1 (en)
JP (1) JPH10502619A (en)
KR (1) KR100379351B1 (en)
CN (1) CN1156964A (en)
AT (1) ATE223224T1 (en)
AU (1) AU689934B2 (en)
BG (1) BG63453B1 (en)
BR (1) BR9508151A (en)
CA (1) CA2192957A1 (en)
CZ (1) CZ381096A3 (en)
DE (1) DE69528064T2 (en)
DK (1) DK0771209T3 (en)
ES (1) ES2182908T3 (en)
FI (1) FI965225A (en)
HK (1) HK1009038A1 (en)
HU (1) HU220877B1 (en)
MX (1) MX9700043A (en)
NO (1) NO965592L (en)
NZ (1) NZ290239A (en)
PL (1) PL186341B1 (en)
PT (1) PT771209E (en)
RO (1) RO116198B1 (en)
RU (1) RU2162855C2 (en)
SK (1) SK164096A3 (en)
UA (1) UA55371C2 (en)
WO (1) WO1996000503A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5962216A (en) * 1994-08-19 1999-10-05 La Region Wallonne Tumor-activated prodrug compounds and treatment
JP2000506494A (en) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド Complexes useful for treating benign prostatic hyperplasia
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
EP0941334B1 (en) * 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
AU7582298A (en) 1997-05-19 1998-12-11 Johns Hopkins University School Of Medicine, The Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EP1036093A1 (en) * 1997-12-02 2000-09-20 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2321171A1 (en) * 1998-03-05 1999-09-10 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
CA2368801A1 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
WO2001025791A2 (en) * 1999-10-07 2001-04-12 Ciphergen Biosystems, Inc. Prostate cancer marker proteins
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
BR0109266A (en) 2000-03-15 2003-04-29 Bristol Myers Squibb Pharma Co Compound, pharmaceutical composition, method of treating a cancer-affected mammal, method of releasing a compound into the cells of a cancer-affected mammal, and use of the compound
EP1294404A2 (en) 2000-06-14 2003-03-26 Corixa Corporation Prodrug compounds with an oligopeptide having an isoleucine residue
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
WO2002081630A2 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of semenogelin in the diagnosis, prognosis and treatment of cancer
ES2388170T3 (en) * 2001-08-24 2012-10-09 Uvic Industry Partnerships Inc. Proaerolysin containing protease activation sequences and methods of use for the treatment of prostate cancer
IL162134A0 (en) * 2001-11-28 2005-11-20 Genset Sa Human cDNAs and proteins, and uses thereof
US7108976B2 (en) * 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
PL212929B1 (en) * 2002-10-31 2012-12-31 Metabasis Therapeutics Inc Novel cytarabine monophosphate prodrugs
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
DK1891093T3 (en) 2005-06-14 2011-07-11 Protox Therapeutics Inc Method of treating or preventing benign prostate hyperplasia using modified pore-forming proteins
JP5278873B2 (en) * 2008-05-14 2013-09-04 国立大学法人九州工業大学 Cancer diagnostic reagents
US9046529B2 (en) 2009-04-10 2015-06-02 The Regents Of The University Of California Prostatitis-associated antigens and methods of use thereof
KR20110069618A (en) * 2009-12-17 2011-06-23 주식회사 셀앤바이오 Kit and method for diagnosis of prostate cancer
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN106687118A (en) 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4277466A (en) * 1978-08-29 1981-07-07 Institut International De Pathologie Cellulaire Et Moleculaire Complexes of DNA and esters derived from daunorubicine, their preparation and use
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
OA06421A (en) * 1980-06-10 1981-09-30 Omnium Chimique Sa Process for the preparation of N- (vinblastinoyl-23) derivatives of amino acids and peptides.
HUT34212A (en) * 1983-04-29 1985-02-28 Omnichem Sa Process for the production of new vindblastin conjugates
FR2546163B1 (en) * 1983-05-16 1987-10-09 Centre Nat Rech Scient NOVEL HYDROSOLUBLE ACYLATED DERIVATIVES OF PEPTIDES OR AMINO ACIDS, THEIR PREPARATION AND THEIR APPLICATION
EP0126344A2 (en) * 1983-05-20 1984-11-28 Abbott Laboratories Tripeptide esters of therapeutic agents
FR2583983B1 (en) * 1985-06-07 1988-05-27 Centre Nat Rech Scient NOVEL WATER-SOLUBLE MACROMOLECULAR PRODUCTS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, ESPECIALLY ANTI-TUMOR AND PEST CONTROL
EP0232693A3 (en) * 1985-12-16 1988-04-06 La Region Wallonne Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them
FR2626882B1 (en) * 1988-02-08 1991-11-08 Ire Celltarg Sa VINCA DERIVATIVE CONJUGATES COMPRISING A DETERGENT CHAIN IN POSITION C-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5220001A (en) * 1989-10-25 1993-06-15 Zaidan Hojim Biseibutsu Dong-A Pharm Co. Anthracycline glycoside derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
SE9002480D0 (en) * 1990-07-23 1990-07-23 Hans Lilja ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN
FR2678274A1 (en) * 1991-06-25 1992-12-31 Medgenix Group Sa N-Leucylepirubicin, application as antitumour medicinal product and process for preparing it
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4233152A1 (en) * 1992-10-02 1994-04-07 Behringwerke Ag Antibody-enzyme conjugates for prodrug activation
EP0667920B1 (en) * 1992-10-29 2003-01-15 Thomas Jefferson University Methods of detecting micrometastasis of prostate cancer
AU6364094A (en) * 1993-03-12 1994-09-26 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
WO1995030758A1 (en) * 1994-05-10 1995-11-16 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5962216A (en) * 1994-08-19 1999-10-05 La Region Wallonne Tumor-activated prodrug compounds and treatment
AUPM769394A0 (en) * 1994-08-25 1994-09-15 Commonwealth Scientific And Industrial Research Organisation Assay for the detection of proteases

Similar Documents

Publication Publication Date Title
WO1996000503B1 (en) Novel peptides
HU9603564D0 (en) Novel peptides
EP0591524A4 (en)
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
CA2050336A1 (en) Yeast processing system comprising a negatively charged amino acid adjacent to the processing site
WO1997028247A3 (en) AMINO ACID-ENRICHED PLANT PROTEIN RESERVES, PARTICULARLY LYSINE-ENRICHED MAIZE η-ZEIN, AND PLANTS EXPRESSING SUCH PROTEINS
EP1623994A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU5222498A (en) Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates
DK0531404T3 (en) Ubiquitin-specific protease
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
AU1003888A (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof
De Camargo et al. Influence of the carboxyl terminus of luteinizing hormone-releasing hormone and bradykinin on hydrolysis by brain endo-oligopeptidases.
EP0528686B8 (en) Process for producing peptides
AU6710998A (en) Process for preparing modified proteins
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
Yonezawa et al. Substrate specificity of cucumisin on synthetic peptides
Bányai et al. Proximity of the catalytic region and the kringle 2 domain in the closed conformer of plasminogen
Levy et al. The digestion of the oxidized B chain of insulin by human neutrophile proteases: elastase and chymotrypsin-like protease
ATE283914T1 (en) IGA1 PROTEASE FRAGMENT AS A CARRIER PEPTIDE
Uddin et al. Specific cleavage of synthetic renin substrate by mouse γ-nerve growth factor
TR199701538T1 (en) Nucleic acid and amino acid sequences of Helibacter pylorus.